AR099437A2 - MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS - Google Patents

MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS

Info

Publication number
AR099437A2
AR099437A2 ARP130103529A ARP130103529A AR099437A2 AR 099437 A2 AR099437 A2 AR 099437A2 AR P130103529 A ARP130103529 A AR P130103529A AR P130103529 A ARP130103529 A AR P130103529A AR 099437 A2 AR099437 A2 AR 099437A2
Authority
AR
Argentina
Prior art keywords
matrix
invariable
sustained
oxycodone
naloxone
Prior art date
Application number
ARP130103529A
Other languages
Spanish (es)
Inventor
spitzley Christoph
Dra Decker Silke
Dra Brgmann Bianca
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR099437A2 publication Critical patent/AR099437A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

Reivindicación 1: Una formulación farmacéutica de almacenamiento estable que comprende una cantidad efectiva de un agonista opioide y un antagonista opioide en una matriz de difusión sustancialmente no hinchable y no erosiva, caracterizada porque comprende etilcelulosa o de polímero basado en etilcelulosa y al menos un alcohol graso, donde dicho agonista opioide es oxicodona y dicho antagonista opioide es naloxona, donde la cantidad de oxicodona presente comprende un rango entre 10 y 150 mg, preferentemente entre 10 y 80 mg, y la cantidad de naloxona presente comprende un rango entre 1 y 50 mg, y donde la oxicodona y la naloxona están presentes en una relación ponderal en peso en un rango entre 5:1 y 1:1.Claim 1: A stable pharmaceutical storage formulation comprising an effective amount of an opioid agonist and an opioid antagonist in a substantially non-swellable and non-erosive diffusion matrix, characterized in that it comprises ethyl cellulose or ethyl cellulose-based polymer and at least one fatty alcohol , wherein said opioid agonist is oxycodone and said opioid antagonist is naloxone, where the amount of oxycodone present comprises a range between 10 and 150 mg, preferably between 10 and 80 mg, and the amount of naloxone present comprises a range between 1 and 50 mg. , and where oxycodone and naloxone are present in a weight ratio in a range between 5: 1 and 1: 1.

ARP130103529A 2002-04-05 2013-09-30 MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS AR099437A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10215067A DE10215067A1 (en) 2002-04-05 2002-04-05 Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation

Publications (1)

Publication Number Publication Date
AR099437A2 true AR099437A2 (en) 2016-07-27

Family

ID=28051126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103529A AR099437A2 (en) 2002-04-05 2013-09-30 MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS

Country Status (2)

Country Link
AR (1) AR099437A2 (en)
DE (1) DE10215067A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP2243471A1 (en) 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015086528A1 (en) * 2013-12-11 2015-06-18 Develco Pharma Schweiz Ag Naloxone mono-product and multi-layer tablet
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
DE202016005375U1 (en) 2015-09-03 2016-09-30 Acino Pharma Ag Reduction of deallylation of naloxone during storage of a naloxone-containing sustained-release formulation

Also Published As

Publication number Publication date
DE10215067A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
AR099437A2 (en) MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS
AR039379A1 (en) MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS
ES2581331T3 (en) Inhibitor of the progression of a disease attributed to an abnormal accumulation of liver fat
WO2000040205A3 (en) Sustained release formulation with reduced moisture sensitivity
BR0107869A (en) Electrogenated pharmaceutical compositions
ES2487496T3 (en) Agent to relieve metabolic syndrome
PT1183014E (en) ORAL PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED LIBERATION AND TISSUE DISSIMULATION
ES2151672T3 (en) QUICK COMPOSITIONS ORAL DISSOLUTION FOR DOPAMINE AGONISTS.
FR2752732B1 (en) EXTENDED RELEASE GALENIC FORM OF MILNACIPRAN
DE60334924D1 (en) ANOTEILCHENGRÖSSE
ES2573539T3 (en) Crystallization inhibitor and its use in gelatin capsules
NZ515359A (en) Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
CO4700474A1 (en) ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE
DE602005025755D1 (en) IRBESARTAN PHARMACEUTICAL COMPOSITION CONTAINING
GT200600023A (en) COMBINATION OF XOLAIR WITH IMMUNOSUPPRESSIVE AGENT
MXPA05007609A (en) CaSR ANTAGONIST.
NO20055601L (en) Pharmaceutical preparation in the form of a hydrogel for transdermal administration of active ingredients
ES2189252T3 (en) ANALGESIC COMPOSITIONS THAT INCLUDE AN ANTAGONIST OF THE COLECISTOQUININE AND AN OPIOID.
MY138975A (en) Novel preparation and administration form comprising an acid-labile active compound
PE123899A1 (en) FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ALPHA-ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
CL2002001701A1 (en) Use of at least one compound selected from melatonin, melatoninergic agents, melatonin agonists and antagonists, in an amount of 0.0025-50 mg, to prepare a useful medicine for the treatment and improvement of the restorative quality of sleep.
DE602004014964D1 (en) PHARMACEUTICAL COMPOSITION WITH A CATIONIC AGENT
KR20110053236A (en) Compositions for percutaneous administration
PT1499278E (en) IMMEDIATE RELEASE PHARMACEUTICAL FORM FOR COMPOSITION OF TIBOLONE POLYMER

Legal Events

Date Code Title Description
FB Suspension of granting procedure